PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care. -
Current and Emerging Therapies for Relapsed and Refractory Multiple Myeloma
Experts review approved therapies and treatments still under investigation. -
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic. -
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
MULTIPLE MYELOMA NEWS
Daratumumab/Hyaluronidase-fihj With Carfilzomib, Dexamethasone Approved for Multiple Myeloma
KRd Plus ASCT Outperforms Other Carfilzomib-Based Regimens in Newly Diagnosed Multiple Myeloma
Indatuximab Ravtansine Has Encouraging Activity in Relapsed/Refractory Multiple Myeloma
Qualitative Study Sheds Light on Patient Trust in Shared Decision Making in MM Treatment
Maintenance Daratumumab May Improve Outcomes vs Observation in Patients With Multiple Myeloma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
Loading... 
Loading...